Myelofibrosis
Advertisement
Efficacy and safety primary analysis findings are reported from the international, open-label FREEDOM2 trial.
Study identifies risks of thrombosis, hemorrhage, and leukemic transformation in patients with myelofibrosis and other MPNs.
Momelotinib and ruxolitinib improved bone marrow fibrosis, but changes were not associated with improved outcomes in MF.
Splenic radiation effectively managed splenomegaly before HSCT for myelofibrosis and significantly reduced relapse afterward.
The study evaluated the impact of mutations on the risk of thromboembolic events, disease progression, and patient mortality.
Fedratinib induced superior spleen volume and symptom response versus best available therapy in patients with myelofibrosis.
Dr. Hobbs shared findings supporting the safety and feasibility of continuing ruxolitinib during and after HSCT for MF.
A pooled study showed treatment with ruxolitinib achieved durable hematocrit control.
Dr. Lucia Masarova described data from SIMPLIFY-1 on medical costs and time burden related to outpatient transfusion in MF.
Ruxolitinib plus navitoclax induced 24-week spleen volume reduction rates twice as high as ruxolitinib plus placebo in MF.
Pelabresib plus ruxolitinib induced significant spleen volume reduction rates without limiting toxicities in myelofibrosis.
Dr. Masarova spoke with HemeToday on findings from a treatment comparison of pacritinib and momelotinib in myelofibrosis.
Treatment using a BET inhibitor as a monotherapy and in combination with appears well-tolerated in myelofibrosis.
Ruben Mesa, MD, spoke at ASCO 2023 about the affect myelofibrosis has on patients’ quality of life.
Zilurgisertib appears safe and well tolerated in patients who have anemia due to myelofibrosis.
A proof-of-concept study indicates the combined use of ruxolitinib and magrolimab is effective in treating myelofibrosis.
The treatment combination of selinexor plus ruxolitinib is effective in treatment-naïve patients with myelofibrosis.
The JAK inhibitor momelotinib appears to have a superior safety profile compared with fedratinib in myelofibrosis.
Patients with myelofibrosis with a certain platelet count who achieve spleen volume reduction on pacritinib have better OS.
The novel JAK1-sparing inhibitor pacritinib is effective at reducing spleen enlargement and disease burden in MF patients.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.